![]() ![]() Our Ai stock analyst implies that there will be a positive trend in the future and the FDMT shares might be good for investing for making money. ![]() Currently there seems to be a trend where stocks in the Healthcare Manufacturing sector(s) have been popular in this period. According to present data 4D Molecular Therapeutics's FDMT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Recommendations: Buy or sell 4D Molecular Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the 4D Molecular Therapeutics share forecasts, stock quote and buy / sell signals below. Real Estate and Housing Market Forecast.Transcript : 4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 Special CallĤDmt to Present Interim Data from 4D-710 Phase 1/2 Aerow Clinical Trial for Cystic Fibrosis Lung Disease At the European Cystic Fibrosis Society 46Th Annual MeetingĤD Molecular Therapeutics, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 02:00 PMīofA Adjusts Price Target on 4D Molecular Therapeutics to $33 From $28, Keeps Buy RatingĤD Molecular Reports Positive Interim Data in Phase 1/2 AEROW Clinical Trial of 4D-710 Shares JumpĤD Molecular Therapeutics Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at ECFS 46th Annual Meeting ![]() ĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000 Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell Microcap Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 2500 Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell Small Cap Comp Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 2000 Growth Index are subject to a Lock-Up Agreement Ending on. Ĭertain Common Stock of 4D Molecular Therapeutics, Inc. Ĭertain Options of 4D Molecular Therapeutics, Inc. ![]() Enter into License Agreement to Use 4Dmt's Proprietary Intravitreal R100 Vector for Rare Ophthalmic TargetsĬhardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price TargetĬertain Warrants of 4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023ĤD Molecular Says Interim Data of 4D-150 Trial Shows Clinical Activity, Favorable Safety Profile in Wet Age-Related Macular Degeneration PatientsĤDMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023ĤD Molecular Completes Enrollment of Phase 2 Trial in Patients with Wet Age-Related Macular DegenerationĬhardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy RatingĤD Molecular Therapeutics Signs License Agreement With Potential Milestones-Linked Fee Options of up to $942.5 MillionĪstellas Pharma Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |